Type: Public Corporation
Our mission is to turn scientific advances in gene therapy into novel treatments for patients with severe degenerative diseases of the eye and the central nervous system.
Our initial focus is on severe retinal diseases, with the goal of preserving or restoring vision in patients who suffer from sight-threatening ophthalmic diseases. We have been using an integrated development platform based on the combination of a gene therapy-based approach with technologies such as Mitochondrial Target Sequence (MTS) and optogenetics. We are proud of the two promising product candidates that, to date, have advanced to the stage of being tested in clinical trials. And we are investigating others.
Offered / Sold Amount
Reported by Press*
Other Relevant Investments
*More data available at: [CB Insights] [CrunchBase] [PitchBook]